Investors' expectations of strong revenue performance and higher forecasted growth than the rest of the Medical Equipment industry are keeping the P/S ratio high. Shareholders' confidence in future revenues suggests the share price won't fall significantly soon.
Investors maintain STAAR Surgical's high P/E, anticipating its market outperformance. The robust earnings forecast revealed by company analysts likely contributes to its high P/E. Shareholders display confidence in future earnings, bolstering share price.
$スターサージカル(STAA.US)$ Many across the world have already gotten ICL implanted into their eyes to correct their Myopia. “Over one million EVO lenses have already been implanted by doctors outside the U.S. and 99.4% of EVO patients in a survey have stated they would have the procedure again. FDA approval brings in the US market, with many prospective users, profits will only go up from here 👍🏻
スターサージカルに関するコメント
The best investment biotech biomed stock
Load any dips below 55
コラムTop upgrades and downgrades on 4/8
• $アフヤ(AFYA.US)$: Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $18)
• $アップフォリオ(APPF.US)$: KeyBanc Upgrades to Overweight from Sector Weight - PT $143
• $シー・エッチ・ロビンソン・ワールドワイド(CHRW.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $117 (from $91)
• $クーパン(CPNG.US)$: Goldman Sachs Upgrades to Conviction Buy from Buy - PT $37
• $ガトス・シルバー(GATO.US)$: RBC Capital Upgrades to Sector Perform from Underperform - PT $4
• $ITT(ITT.US)$: UBS Upgr...
コラムToday's pre-market stock movers: TSLA, AAPL, POLY and more
• $Plantronics(POLY.US)$ +50% (to be acquired by HP Inc ($HPインク(HPQ.US)$) for $40.00 per share)
• $アクサム・セラピューティクス(AXSM.US)$ +21.6% (Jazz Pharma divests Sunosi to Axsome Therapeutics)
• $スターサージカル(STAA.US)$ +15.4% (receives FDA approval of EVO Visian Implantable Collamer Lenses)
• $Sarcos Technology & Robotics(STRC.US)$ +7.6% (announces that the Company has reached a definitive merger agreement to acquire Pittsburgh-base...
Fantastic News!!!
Many across the world have already gotten ICL implanted into their eyes to correct their Myopia.
“Over one million EVO lenses have already been implanted by doctors outside the U.S. and 99.4% of EVO patients in a survey have stated they would have the procedure again.
FDA approval brings in the US market, with many prospective users, profits will only go up from here 👍🏻
コラムTop upgrades and downgrades on 3/18
• $オールステート(ALL.US)$: Raymond James Upgrades to Strong Buy from Outperform - PT $165 (from $145)
• $デジタルブリッジ・グループ(DBRG.US)$: JPMorgan Upgrades to Neutral from Underweight - PT $7
• $ガーミン(GRMN.US)$: BofA Securities Upgrades to Buy from Neutral - PT $140 (from $165)
• $ガイドワイア・ソフトウェア(GWRE.US)$: JMP Securities Upgrades to Market Outperform from Market Perform - PT $110
• $モンゴDB(MDB.US)$: UBS Upgrades to Buy from Neutral - PT $450 (from $345)...
まだコメントはありません